TLSA - Tiziana Life Sciences PLC

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
7.15
-0.18 (-2.46%)
At close: 2:44PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close7.33
Open7.48
Bid6.55 x 1800
Ask11.00 x 800
Day's Range6.66 - 7.48
52 Week Range5.00 - 12.17
Volume1,988
Avg. Volume3,074
Market Cap109.764M
Beta (3Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
  • Business Wirelast month

    Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Clinical Trial with Milciclib in Patients With Advanced Liver Cancer

    NEW YORK & LONDON-- -- 80% of patients who completed treatment within the trial’s timeframe requested to continue treatment on compassionate use grounds Independent Data Monitoring Committee finds no unexpected signs or signals of toxicity Top line data expected Q3 2019 Tiziana Life Sciences plc , a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation ...

  • Benzinga2 months ago

    The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 19) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...

  • GlobeNewswire2 months ago

    Tiziana Submits IND Application for Oral Formulation of Foralumab for Treatment of NASH

    AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology and immunology, today announced that it has submitted* an Investigational New Drug application ("IND") to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers. Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), is being developed for the treatment of autoimmune and inflammatory diseases such as nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).

  • GuruFocus.com5 months ago

    Nasdaq Keeps Momentum, Other Indexes Close Lower Tuesday

    Nasdaq Composite closes at 7,031.83 with a gain of 0.16%

  • Business Wire6 months ago

    Tiziana Completes Patient Enrollment in a Phase 2a Trial to Evaluate Tolerability and Anti-Tumor Activity of Milciclib in Hepatocellular Carcinoma (HCC)

    Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing Phase 2a clinical trial (CDKO-125A-010) is completed. Topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019. It was concluded by an Independent Data Monitoring Committee (IDMC) that there were no major signals of tolerability concerns, and the IDMC allowed continuation of patient enrollment in the trial.

  • Business Wire6 months ago

    Tiziana Announces Initiation of Phase 1 Clinical Trial with Nasal Administration of Foralumab, a Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 mAb), in Healthy Volunteers

    Tiziana Life Sciences plc (“Tiziana” or the “Company”) (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, previously announced that it had submitted an Investigational New Drug (IND) application on 1 June 2018 to the U.S. Food and Drug Administration (FDA). Following approval of the IND application by the FDA, the Company announces that a first-in-human Phase 1 clinical trial in healthy volunteers has been initiated at the Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.

  • Business Wire6 months ago

    Tiziana Announces Closing of Offering and Resulting Total Voting Rights

    Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the closing of its underwritten, registered public offering in the United States (the “Offering”) of 442,910 American Depositary Shares ("ADSs"), representing 4,429,100 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares") at a price of $9.90 per ADS, for aggregate gross proceeds of approximately £3.42 million (or $4.39 million at a GBP1 : US$1.2839 exchange rate), before deducting underwriting discounts and commissions. Each ADS offered represents 10 Ordinary Shares.

  • Business Wire6 months ago

    Tiziana Announces Pricing of Offering and Warrant Conversion Raising in Aggregate $5.79 million of New Equity Capital, Approval to List on the Nasdaq Global Market and Loan Conversion Extinguishing $1.78 million of Debt

    Tiziana Life Sciences plc (TILS.L) (the "Company" or "Tiziana"), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the pricing of its underwritten initial public offering in the United States (the “Offering”) of 442,910 American Depositary Shares ("ADSs"), representing 4,429,100 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares") at an initial public offering price of $9.90 per ADS, before underwriting discounts and commissions. Each ADS offered represents 10 Ordinary Shares.